These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27868164)

  • 1. Efficient production of recombinant glycoprotein D of herpes simplex virus type 2 in Pichia pastoris and its protective efficacy against viral challenge in mice.
    Wang M; Jiang S; Zhou L; Wang C; Mao R; Ponnusamy M
    Arch Virol; 2017 Mar; 162(3):701-711. PubMed ID: 27868164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of recombinant herpes simplex virus 1 glycoprotein D candidate vaccines in mice.
    Durmanová V; Mosko T; Sapák M; Kosovský J; Rezuchová I; Buc M; Rajcáni J
    Acta Microbiol Immunol Hung; 2006 Dec; 53(4):459-77. PubMed ID: 17278713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
    Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
    PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Construction and Immunogenicity Analysis of Herpes Simplex Virus Type 2 Glycoprotein D Recombinant Adenovirus Vaccine].
    Liu W; Zhao D; Wang Z; Li Y; Wang H; Wang H
    Bing Du Xue Bao; 2016 May; 32(3):267-72. PubMed ID: 29962197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCL19 and CCL28 Assist Herpes Simplex Virus 2 Glycoprotein D To Induce Protective Systemic Immunity against Genital Viral Challenge.
    Yan Y; Hu K; Fu M; Deng X; Luo S; Tong L; Guan X; He S; Li C; Jin W; Du T; Zheng Z; Zhang M; Liu Y; Hu Q
    mSphere; 2021 Apr; 6(2):. PubMed ID: 33910988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus.
    Du R; Wang L; Xu H; Wang Z; Zhang T; Wang M; Ning Y; Deng F; Hu Z; Wang H; Li Y
    Antiviral Res; 2017 Nov; 147():131-141. PubMed ID: 29061442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice.
    Akhrameyeva NV; Zhang P; Sugiyama N; Behar SM; Yao F
    J Virol; 2011 May; 85(10):5036-47. PubMed ID: 21389121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone.
    Meseda CA; Elkins KL; Merchlinsky MJ; Weir JP
    J Infect Dis; 2002 Oct; 186(8):1065-73. PubMed ID: 12355355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and immunogenicity of recombinant glycoprotein D of herpes simplex virus 1 in Drosophila S2 cells.
    Mao H; Zhao X; Zhu H; Guo J; Ma Z
    Prep Biochem Biotechnol; 2016 May; 46(4):384-91. PubMed ID: 26835587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of protective immune responses to the glycoprotein H-glycoprotein L complex of herpes simplex virus type 1.
    Browne H; Baxter V; Minson T
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2813-7. PubMed ID: 8277292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.
    Ramsey NLM; Visciano M; Hunte R; Loh LN; Burn Aschner C; Jacobs WR; Herold BC
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
    Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
    J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.
    Awasthi S; Zumbrun EE; Si H; Wang F; Shaw CE; Cai M; Lubinski JM; Barrett SM; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
    J Virol; 2012 Apr; 86(8):4586-98. PubMed ID: 22318147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.
    Wang K; Goodman KN; Li DY; Raffeld M; Chavez M; Cohen JI
    J Virol; 2016 Jan; 90(1):562-74. PubMed ID: 26559846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of B- and T-cell epitopes from glycoprotein B of herpes simplex virus 2 and evaluation of their immunogenicity and protection efficacy.
    Liu K; Jiang D; Zhang L; Yao Z; Chen Z; Yu S; Wang X
    Vaccine; 2012 Apr; 30(19):3034-41. PubMed ID: 22008818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.